Trends in human immunodeficiency virus seroprevalence among injection drug users entering drug treatment centers, United States, 1988-1993

American Journal of Epidemiology

Volumn 143, Issue 7, 1996, Pages 733-742

  Prevots, D Rebecca ^a,c   Allen, David M ^b   Lehman, J Stan ^a   Green, Timothy A ^a   Petersen, Lyle R ^a   Gwinn, Marta ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

acquired immunodeficiency syndrome; HIV seroprevalence; HIV 1; substance abuse, intravenous

Indexed keywords

ADULT; ARTICLE; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; RACE DIFFERENCE; RISK ASSESSMENT; UNITED STATES;

EID: 0030009562     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008807     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. Update: trends in AIDS diagnosis and reporting under the expanded surveillance definition for adolescents and adults-United States, 1993. MMWR 1994;43:826-31.
2. Centers for Disease Control and Prevention. Update: AIDS among women - United States, 1994. MMWR 1995;44:81-4.
3. Prevots DR, Ancelle-Park RA, Neal JJ, et al. The epidemiology of heterosexually acquired HIV infection and AIDS in Western industrialized countries. AIDS 1994;8:S109-17.
4. Jones TS, Allen DM, Onorato IM, et al. HIV seroprevalence surveys in drug treatment centers. Public Health Rep 1990; 105:125-30.
5. Harris NV, Thiede H, McGough P, et al. Risk factors for HIV infection among injection drug users: results of blinded surveys in drug treatment centers, King County, Washington, 1988-1991. J Acquir Immune Defic Syndr 1993;6:1275-82.
6. Centers for Disease Control and Prevention. Uses of data. In: National HIV Serosurveillance Summary: results through 1992. Vol. 3. Atlanta, GA: US Department of Health and Human Services, 1994.
7. Allen DM, Onorato IM, Green TA. HIV infection in intravenous drug users entering drug treatment United States, 1988 to 1989. Am J Public Health 1992:82:541-6.
8. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
9. Weinstock HS, Sidhu J, Gwinn, et al. Trends in HIV seroprevalence among persons attending sexually transmitted disease clinics in the United States, 1988-1992. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:514-22.
10. Nicolosi A, Leite MLC, Molinari S, et al. Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centers in Milan and northern Italy, 1986-1990. J Acquir Immune Defic Syndr 1992;5:365-73.
11. Nelson KE, Vlahov D, Solomon L, et al. Temporal trends of incident HIV infection in a cohort of injection drug users in Baltimore, Maryland. Arch Intern Med 1995;155:1305-11.
12. Moss AR, Vranizan K, Goner R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994;8:223-31.
13. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA 1994;271:121-7.
14. Galli M, Musicco M. Mortality of intravenous drug users living in Milan, Italy: role of HIV infection. AIDS 1994;8: 1457-63.
15. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.
16. Battjes R, Leukfeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992;18:263-73.
17. Mariotto AB, Mariotti S, Pezzotti P, et al. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992;135:428-37.
18. Chang HG, Morse DL, Noonan C, et al. Survival and mortality patterns of an acquired immunodeficiency syndrome (AIDS) cohort in New York State. Am J Epidemiol 1993;138:341-9.
19. Neal JJ, Fleming PL, Green TA, et al. Survival among injecting drug users with AIDS, United States, 1988-1990. (Abstract PC0126). Tenth international conference on AIDS. Yokohama, Japan, August 1994.
20. Watters JK, Estilo MJ, Clark CL, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115-20.
21. Vlahov D, Anthony JC, Celentano D, et al. Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987. Am J Drug Alcohol Abuse 1991;17:39-48.
22. Battjes RJ, Pickens RW, Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities. J Acquir Immune Defic Syndr 1991;4:1148-54.
23. Battjes RJ, Pickens RW, Haverkos HW, et al. HIV risk factors among injecting drug users in five US cities. AIDS 1994;8: 681-7.
24. Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989;261:561-5.
25. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989;321:874-9.
26. Hahn RA, Onorato IM, Jones TS, et al. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989;261:2677-84.
27. Edlin B, Irwin K, Faruque S, et al. Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994;331:1422-7.
28. Des Jarlais DCD, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989;261: 1008-12.
29. Romano N, Vitale F, Alesi DR, et al. The changing pattern of human immunodeficiency virus type 1 infection in intravenous drug users. Results of a six-year seroprevalence study in Palermo, Italy. Am J Epidemiol 1992;135:1189-96.
30. Kitayapom D, Uneklabh C, Weniger BG, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994;8:1443-50.
31. Robertson JR, Bucknall ABV, Welsby PD, et al. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug users. Br Med J 1986;292:527-9.
32. Zaccareili M, Rezza G, Girardi E, et al. Monitoring HIV trends in injecting drug users: an Italian experience. AIDS 1990;4:1007-10.
33. Longshore D, Anglin MD. HIV prevalence and incidence among injection drug users in Los Angeles. (Letter). J Acquir Immune Defic Syndr 1994;7:738-9.
34. Kerndt PR, Weber MD, Ford W, et al. Estimated HIV incidence in a cohort of injection drug users in Los Angeles, California. (Letter). JAMA 1995;273:1831-2.
35. National Institute on Drug Abuse. Epidemiologic trends in drag abuse. Vol. 1. Highlights and executive summary. Community epidemiology work group, June 1994. Rockville, MD: National Institute for Drug Abuse, 1994. (Publication no. 94-3853).
36. Van Ameijden EJC, Van den Hoek JAR, Hartgers C, et al. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol 1994;139:1153-63.
37. Des Jarlais DC, Casriel C, Friedman SR, et al. AIDS and the transition to illicit drug injection - results of a randomized trial prevention program. Br J Addict 1992;87:493-8.
38. Chen K, Kandel DB. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health 1995;85:41-7.
39. Lurie P, Reingold AC, Bowser B, et al. The public health impact of needle exchange programs in the United States and abroad. Vol. 1. Atlanta GA: Centers for Disease Control and Prevention, 1993.
40. Valleroy LA, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales - Connecticut, 1992-1993. J Acquir Immun Defic Syndr Hum Retrovirol 1995;10:73-81.
41. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers-Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:82-9.